终末期肾病血液透析血管通路:经皮腔内前臂动静脉内瘘的前瞻性多中心NEAT试验
NEAT研究是一项前瞻性单臂多中心试验,在加拿大、澳大利亚和新西兰的9个中心纳入80例需建立血管通路的成人患者(20例导入期,60例全分析集)。采用导管型射频磁科技在目标血管间建立吻合,形成经皮腔内动静脉内瘘(endoAVF)。结果显示,endoAVF创建成功率98%,8%发生严重操作相关不良事件(2%与器械相关),87%在3个月内生理上适合透析,12个月原发通畅率69%、累积通畅率84%。
要点
- 经皮腔内前臂动静脉内瘘创建成功率高(98%),严重操作相关不良事件发生率低(8%)。
- 87%的endoAVF在3个月内生理上适合透析(肱动脉血流≥500mL/min,静脉直径≥4mm)。
- endoAVF 12个月原发通畅率69%,累积通畅率84%,可能成为血液透析血管通路的替代选择。
核心结论
- 使用射频磁导管系统可可靠创建endoAVF,无需开放手术,并发症少。
- endoAVF可成功用于血液透析,并显示高12个月累积通畅率。
- 对于需要血管通路的血液透析患者,endoAVF可能是可行的替代选择。
研究设计与样本
- 前瞻性、单臂、多中心研究(NEAT试验),在加拿大、澳大利亚和新西兰的9个中心进行。
- 纳入连续成人的非透析依赖和透析依赖患者,因血管通路创建转诊。
- 80例患者入组(20例导入期和60例全分析集,本报告为后者)。
主要发现
- 98%的参与者成功创建endoAVF。
- 8%发生严重操作相关不良事件,其中2%与器械相关。
- 87%的endoAVF在3个月内生理上适合透析(平均肱动脉血流918mL/min,头静脉直径5.2mm)。
- 在接受透析的参与者中,endoAVF功能可用性为64%。
- 12个月原发通畅率和累积通畅率分别为69%和84%。
关键数值与推荐
- 生理适合透析标准:肱动脉血流≥500mL/min,静脉直径≥4mm。
临床怎么用
- endoAVF可作为需要血液透析血管通路患者的替代选择,尤其在不适合开放手术时。
- 术后需评估肱动脉血流和静脉直径以判断生理适合性。
- 需关注操作相关不良事件,尤其是器械相关事件。
局限性
- 由于endoAVF的独特解剖和所用血管,本研究为单臂研究,无外科对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemodialysis arteriovenous fistulas (AVFs) are suboptimally used primarily due to problems with maturation, early thrombosis, and patient nonacceptance. An endovascular approach to fistula creation without open surgery offers another hemodialysis vascular access option. STUDY DESIGN: Prospective, single-arm, multicenter study (Novel Endovascular Access Trial [NEAT]). SETTINGS & PARTICIPANTS: Consecutive adult non-dialysis-dependent and dialysis-dependent patients referred for vascular access creation at 9 centers in Canada, Australia, and New Zealand. INTERVENTION: Using catheter-based endovascular technology and radiofrequency energy, an anastomosis was created between target vessels, resulting in an endovascular AVF (endoAVF). OUTCOMES: Safety, efficacy, functional usability, and patency end points. MEASUREMENTS: Safety as percentage of device-related serious adverse events; efficacy as percentage of endoAVFs physiologically suitable (brachial artery flow ≥ 500mL/min, vein diameter ≥ 4mm) for dialysis within 3 months; functional usability of endoAVFs to provide prescribed dialysis via 2-needle cannulation; primary and cumulative endoAVF patencies per standardized definitions. RESULTS: 80 patients were enrolled (20 roll-in and 60 participants in the full analysis set; the latter are reported). EndoAVFs were created in 98% of participants; 8% had a serious procedure-related adverse event (2% device related). 87% were physiologically suitable for dialysis (eg, mean brachial artery flow, 918mL/min; endoAVF vein diameter, 5.2mm [cephalic vein]). EndoAVF functional usability was 64% in participants who received dialysis. 12-month primary and cumulative patencies were 69% and 84%, respectively. LIMITATIONS: Due to the unique anatomy and vessels used to create endoAVFs, this was a single-arm study without a surgical comparator. CONCLUSIONS: An endoAVF can be reliably created using a radiofrequency magnetic catheter-based system, without open surgery and with minimal complications. The endoAVF can be successfully used for hemodialysis and demonstrated high 12-month cumulative patencies. It may be a viable alternative option for achieving AVFs for hemodialysis patients in need of vascular access.
引用
- Lok CE, Rajan DK, Clement J, et al. Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). Am J Kidney Dis. 2017. PMID: 28624422. doi:10.1053/j.ajkd.2017.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。